Evidence map›Paper›PMID 35576074›Full record

ArticleCancer immunology, immunotherapy : CII2022

Checkpoint-inhibitor induced Polyserositis with Edema.

Sarah Zierold, Larissa Semra Akcetin, Eva Gresser, Anna Marie Maier, Alexander König, Rafaela Kramer, Sebastian Theurich, Dirk Tomsitz, Michael Erdmann, Lars E French and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 3 countries.

Sarah ZieroldDepartment of Dermatology and Allergy, University Hospital, LMU Munich, Frauenlobstraße 9-11, 80337, Munich, Germany.
Larissa Semra AkcetinDepartment of Dermatology and Allergy, University Hospital, LMU Munich, Frauenlobstraße 9-11, 80337, Munich, Germany.
Eva GresserDepartment of Radiology, University Hospital, LMU Munich, Munich, Germany.
Anna Marie MaierDepartment of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany.
Alexander KönigDepartment of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany.
Rafaela Kramer.
Sebastian TheurichDepartment of Medicine III, University Hospital, LMU Munich, Munich, Germany.
Dirk TomsitzDepartment of Dermatology and Allergy, University Hospital, LMU Munich, Frauenlobstraße 9-11, 80337, Munich, Germany.
Michael ErdmannDepartment of Dermatology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Universitätsklinikum Erlangen, Erlangen, Germany.
Lars E FrenchDepartment of Dermatology and Allergy, University Hospital, LMU Munich, Frauenlobstraße 9-11, 80337, Munich, Germany.
Martina RudeliusInstitute of Pathology, Ludwig-Maximilians-Universität München, Munich, Germany.
Lucie HeinzerlingDepartment of Dermatology and Allergy, University Hospital, LMU Munich, Frauenlobstraße 9-11, 80337, Munich, Germany. Lucie.Heinzerling@med.uni-muenchen.de.ORCID http://orcid.org/0000-0001-5718-3643
LMU Klinikum · DEFriedrich-Alexander-Universität Erlangen-Nürnberg · DEGerman Cancer Research Center · DELudwig-Maximilians-Universität München · DEUniversity of Lucerne · CHUniversity of Miami · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAs immune checkpoint inhibitors (ICI) are increasingly being used due to effectiveness in various tumor entities, rare side effects occur more frequently. Pericardial effusion has been reported in patients with advanced non-small cell lung cancer (NSCLC) after or under treatment with immune checkpoint inhibitors. However, knowledge about serositis and edemas induced by checkpoint inhibitors in other tumor entities is scarce. METHODS AND

resultsFour cases with sudden onset of checkpoint inhibitor induced serositis (irSerositis) are presented including one patient with metastatic cervical cancer, two with metastatic melanoma and one with non-small cell lung cancer (NSCLC). In all cases treatment with steroids was successful in the beginning, but did not lead to complete recovery of the patients. All patients required multiple punctures. Three of the patients presented with additional peripheral edema; in one patient only the lower extremities were affected, whereas the entire body, even face and eyelids were involved in the other patients. In all patients serositis was accompanied by other immune-related adverse events (irAEs).

conclusionICI-induced serositis and effusions are complex to diagnose and treat and might be underdiagnosed. For differentiation from malignant serositis pathology of the punctured fluid can be helpful (lymphocytes vs. malignant cells). Identifying irSerositis as early as possible is essential since steroids can improve symptoms.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsSerositisEdemaHumansImmune Checkpoint InhibitorsImmune Checkpoint InhibitorsAnti-PD1-antibodyAutoimmunityPericardial effusionPleural effusionSerositisSide effects

Identifiers

PMID35576074
PMCPMC9588471
OpenAlexW4280553421

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.